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Abstract: Infectious diseases caused by microbial biofilms are a major clinical problem, and new
antimicrobial agents that can inhibit biofilm formation and eradicate pre-formed biofilms are urgently
needed. Pomegranate extracts are a well-established folkloric medicine and have been used in the
treatment of infectious diseases since ancient times, whilst the addition of metal ions, including
zinc (II), has enhanced the antimicrobial activity of pomegranate. Micrococcus luteus is generally a
non-pathogenic skin commensal bacterium, although it can act as an opportunistic pathogen and
cause serious infections, particularly involving catheterization and comorbidities. The aims of this
study were to evaluate the holistic activity of pomegranate rind extract (PRE), Zn (II), and PRE/Zn
(II) individually and in combination against M. luteus under both planktonic and biofilm conditions.
Antimicrobial activity was detected in vitro using the broth dilution method, and synergistic activity
was determined using checkerboard and time-kill assays. Effects on biofilm formation and eradication
were determined by crystal violet and BacLightTM Live/Dead staining. PRE and Zn (II) exerted
antimicrobial activity against M. luteus under both planktonic and biofilm conditions. After 4 h, potent
synergistic bactericidal activity was also found when PRE and Zn (II) were co-administered under
planktonic conditions (log reductions: PRE 1.83 ± 0.24, Zn (II) 3.4 ± 0.08, and PRE/Zn (II) 6.88 ± 1.02;
p < 0.0001). In addition, greater heterogeneity was induced in the structure of M. luteus biofilm using
the PRE/Zn (II) combination compared to when PRE and Zn (II) were applied individually. The
activity of PRE and the PRE/Zn (II) combination could offer a novel antimicrobial therapy for the
treatment of disease-associated infections caused by M. luteus and potentially other bacteria.
Keywords: pomegranate rind extract; zinc (II); synergistic activity; Micrococcus luteus; biofilm;
pathogens; catheter; polyphenols; punicalagin
1. Introduction
Biofilm-related infections are one of the major problems for the economies and health
of societies worldwide [1,2]. Biofilms are aggregations of microorganisms, where the
cells are embedded within a self-produced matrix or extracellular polymeric substances
(EPS) [3]. In addition, microorganisms within a biofilm are less sensitive to antimicrobial
agents and antibiotics than when in their planktonic states [4]. Micrococcus species can form
biofilms on a variety of surfaces, such as human skin, soil, and medical devices [5,6]. While
generally accepted as non-pathogenic, M. luteus can cause infection as an opportunistic
pathogen, especially in immuno-suppressed patients with other comorbidities [7–12].
It has been reported that M. luteus is associated with septic arthritis, prosthetic valve
endocarditis, and recurrent bacteremia [13]. Moreover, while M. luteus is considered
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to be an abundant commensal microbe in healthy skin, it has been found to enhance
S. aureus pathogenesis [14,15]. In one case report, a patient with native valve endocarditis
due to M. luteus infection was unsuccessfully treated with vancomycin, gentamicin, and
rifampicin [16]. In addition, MDR bacteria represent an enormous global problem in clinical
settings, with resistance also being reported with M. luteus [17,18]. Hence, while M. luteus
is currently susceptible to a range of antibiotics, resistance has been reported for ampicillin
and erythromycin [19]. There are an increasing number of reports showing that M. luteus
can cause severe infections such as pneumonia, ventricular shunt-related meningitis, septic
arthritis, bacteremia, peritonitis, and endocarditis in immunosuppressive patients [20].
Though typically of low virulence, M. luteus may become pathogenic in patients with
impaired resistance, such as by colonizing the surface of heart valves [21]. Catheter-related
infections are also a challenging medical problem because catheters can be colonized by
commensal microorganisms that are found in the skin surrounding the site of catheter
insertion [22,23]. M. luteus naturally colonizes the skin, mucosae, and oropharynx and has
been associated with such infections related to catheterization [10].
Plant extracts continue to be examined as sources of novel antimicrobial agents.
Pomegranate (Punica granatum) is part of the Punicaceae family native to the Middle
East and cultivated in various parts of the world [24]. Pomegranate is a well-established
folklore medicine, and it has been used as a traditional medicine for the treatment of
dysentery, diarrhea, and stomatitis in many cultures [25]. Recent studies have shown that
pomegranate demonstrates benefits in treating numerous conditions due to its anticancer,
antimicrobial, anti-inflammatory and antioxidant activities [26]. The pomegranate exocarp,
or rind, is abundant in hydrolysable tannins, or ellagitannins, and these compounds have
been attributed as being the primary sources of bioactivity responsible for the beneficial
medicinal properties of pomegranate [25]. In particular, punicalagin (Figure 1), a large
ellagitannin with a molecular weight of 1084.71, has shown antimicrobial activity against a
variety of microorganisms [26–28].







Figure 1. (a) Representative HPLC chromatogram of pomegranate rind extract (PRE). Note: the α and β anomers of 
punicalagin are in a characteristic 1:2 ratio. (b) Chemical structure of punicalagin. 
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The combination of antimicrobials with metal ions has offered beneficial novel ap-
proaches to treat bacterial infections and in the fight against multi drug resistant (MDR)
bacteria [26]. The enhancement of the anti-bacteriophage and antimicrobial activities of
pomegranate rind extract (PRE) in combination with metal salts has been reported in
several studies, including synergistic (potentiated) virucidal activity against Herpes simplex
virus I and II [28–31]. Based on these previous findings, this study evaluated the holistic ac-
tivity of PRE (rather than its individual chemical constituents), Zn (II), and the combination
of PRE/Zn (II) against planktonic bacteria, namely M. luteus. We then aimed to determine
the effects of these substances against M. luteus pre-formed biofilm and biofilm formation.
2. Materials and Methods
2.1. Materials
Pomegranates (of Spanish origin) were obtained from a local supermarket. Zn (II), as
zinc sulfate heptahydrate (ZnSO4·7H2O), and potassium hydrogen phthalate were obtained
from ThermoFisher Scientific (Loughborough, UK). Punicalagin (≥98%), Folin–Ciocalteu
(F–C) reagent, ascorbic acid, and sodium carbonate (Na2CO3) were all obtained from
Sigma-Aldrich (Gillingham, UK). Mueller–Hinton broth (MH broth), Mueller–Hinton agar
(MH agar), and Brain–Heart Infusion agar (BHIA) were obtained from Oxoid (Basingstoke,
UK). The Live/Dead BacLightTM Bacterial Viability Kit was obtained from Invitrogen
Molecular Probes (Paisley, UK).
2.2. Preparation of Pomegranate Rind Extract (PRE)
Pomegranate rinds were removed using a scalpel and cut to approximately 2 cm2
pieces. Then, 300 g of rind were blended (25% w/v) in deionized water in a standard
blender until visibly homogeneous. This was then boiled for 10 min and centrifuged
four times using a Heraeus Multifuge 3S/3S-R centrifuge (5980× g at 4 ◦C for 30 min)
before being filtered through 0.45-µm Whatman nylon membrane filter. The filtrate was
then freeze-dried, protected from light, and stored at −20 ◦C until required. The desired
concentration of PRE was prepared in a pH 4.5 phthalate buffer and sterilized by using a
0.45 µm Millex-FG syringe-driven filter [32]. PRE and Zn (II) stock solutions were prepared
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in a phthalate buffer at pH 4.5, then diluted in MH broth to the desired concentrations,
and sterilized.
2.3. Characterization of PRE
The total phenolic content of PRE was determined using a modified version of the
previously described Folin–Ciocalteu colorimetric method [33]. Briefly, 500 mg/L PRE
samples were prepared, and 200 µL of 10% (v/v) F–C reagent were added to 100 µL of the
prepared PRE samples, followed by the addition of 800 µL of 700 mM Na2CO3. After 2 h
of incubation at room temperature, 200 µL of each sample were added to 96-well plates,
and the absorbance values were read at 760 nm using a plate reader (Fluostar Optima,
BMG Labtech, Aylesbury, UK). The results were expressed as tannic acid equivalent (TAE)
per gram of freeze-dried sample. Punicalagin concentrations were determined by HPLC
analysis performed with an Agilent 1100 system fitted with a Kinetex C18 150× 4.6 mm
5µm 100 Å RP column (Phenomenex, Macclesfield, UK) based on the method reported by
Seeram et al. [34].
2.4. Microorganism and Test Solutions
Micrococcus luteus 59 PIM was used in this study, and its identity was confirmed using
a Bruker MALDI Biotyper identification protocol (Bruker Daltonik, Bremen, Germany)
(Supplementary Data). Bacteria were grown on either MH agar or BHIA. MH broth was
used for overnight cultures, and the stationary-phase inoculum was obtained by inoculating
10 mL of broth for around 20 h at 37 ◦C under aerobic conditions for each experiment.
This was diluted with sterile MH broth to obtain 0.08–0.1 of OD600 corresponding to
108 CFU/mL. This OD600 range was confirmed by plate count.
PRE and Zn (II) stock solutions were prepared in a pH 4.5 phthalate buffer and
then diluted in MH broth (a 10% pH 4.5 phthalate buffer in highest concentrations of
working PRE and Zn (II) samples). Only MH broth was added as a sterility control and
a 10% phthalate buffer in MH broth was added to observe any possible antimicrobial
effect of phthalate buffer pH 4.5 to all microbiology tests. No antimicrobial effect was
observed with 10% phthalate buffer in the MH broth. PRE/Zn (II) combination solutions
for assays were prepared by combining equal volumes (1:1) of PRE and Zn (II). PRE/Zn
(II) (2xMIC + 2xMIC) was prepared by combining same volume of PRE (4xMIC) and Zn
(II) (4xMIC) for biofilm inhibition assay as it will be diluted again when it was added
on the same volume of bacterial suspension. PRE/Zn (II) (MIC + MIC) was prepared by
adding equal volumes of PRE (2 × MIC) and Zn (II) (2 × MIC). Similarly, PRE/Zn (II)
(MIC/2 + MIC/2) was prepared by adding equal volumes of PRE (1 × MIC) and Zn (II)
(1 × MIC).
2.5. Microdilution Method
The minimum inhibitory concentrations (MICs) of the test substances were deter-
mined using the broth microdilution method, according to standard guidelines of the
CLSI [35]. Overnight cultures of M. luteus were prepared in an MH broth until turbid and
corresponding to 106 CFU/mL. The serial dilutions of PRE (976–25,000 mg/L) and Zn
(II) (2246–28,760 mg/L) were prepared in a 96-well plate using MH broth as a diluent. A
100 µL volume of prepared bacterial suspension was added to each well, which included
the same volume of serially diluted compounds. The prepared plates were incubated at
37 ◦C under aerobic conditions. After 24 h, the plates were also visually evaluated to
determine the MIC values as the lowest compound concentrations that inhibited microbial
growth. The minimum bactericidal concentration (MBC) was determined according to
CLSI guidelines [36]. Briefly, the MBC values for the compounds were determined as the
lowest concentration at which no growth was observed in 24 h.
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2.6. In Vitro Evaluation Synergistic/Antagonistic Activity of PRE and Zn (II)
2.6.1. Checkerboard Assay
The potential for synergism between PRE and Zn (II) was evaluated using a checker-
board assay [37]. The test was performed in MH broth using 96-well microtiter plates
containing two-fold serial concentrations of PRE and Zn (II). Then, a bacterial solution was
prepared to obtain a final inoculate of 5 × 105 CFU/mL for each well, and plates were
incubated for 24 h at 37 ◦C under aerobic conditions. At the end of the incubation period,
the wells were visually examined and the MICs recorded for PRE, Zn (II), and PRE/Zn (II)
in combination. Each test was performed in triplicate. The observed MIC values were used
to calculate the fractional inhibitory concentration (FIC) of each compound. The FIC value
was calculated by dividing the MIC value of the compound in combination with the MIC
value of the compound alone. Then, the FIC values of each test substance were added to
find the FICindex, as per the following formula:
FIC value of compound A; FICA = (MICA in combination)/(MICA alone)
FIC value of compound B; FICB = (MICB in combination)/(MICB alone)
The FICindex = FICA + FICB FICindex values were interpreted as synergy for FICin-
dex < 0.5, no interaction for 1 < FICindex < 4, or antagonistic for FICindex > 4 [38].
2.6.2. Time-Kill Assay
Time-kill assays against M. luteus were performed at four time points (10, 30, 60, and
240 min) for half the MIC (MIC/2) values calculated for PRE, Zn (II), and the PRE/Zn
(II) combination. Compounds and their combinations were incubated with 106 CFU/mL
of bacteria at 37 ◦C under aerobic conditions. At each time-point, a sterilized universal
quenching agent (0.1% peptone, 0.1% sodium thiosulphate, 0.5% Tween 80, and 0.07%
lecithin w/v at pH 7) [39] was added to each sample and diluted in sterile phosphate-
buffered saline (pH 7.2) for viable bacterial count determination using the Miles and Misra
method [40]. Each experiment was repeated twice for three independent experiments, and
data are expressed as mean log reduction ± SEM.
2.7. In Vitro Biofilm Inhibition and Eradication Activity of PRE, Zn (II), and PRE/Zn
(II) Combination
2.7.1. Biofilm Inhibition and Eradication Assay
Biofilm formation was quantified in 96-well plates with standard crystal violet stain-
ing using an adaptation of a previously reported biofilm inhibition spectrophotometric
assay [41]. Plates were prepared with 100 µL of M. luteus suspension (108 CFU/mL), and
100 µL of PRE, Zn (II) and PRE/Zn (II) combinations were added into the wells to obtain
MIC and MIC/2 values as final concentrations of compounds and combinations for testing,
as described in Section 2.4. In addition, a background plate was prepared for specified
concentrations of compounds and combinations without bacterial inoculation. Plates were
incubated for 24 h at 37 ◦C under aerobic conditions. After 24 h, the liquid suspensions
were removed and a 100 µL 1% v/v aqueous solution of crystal violet was added and
incubated for 30 min at room temperature. Then, the dye was removed, the wells washed
thoroughly, and 95% ethanol was added and incubated for 20 min. The violet solution
was spectrophotometrically determined at 570 nm, as described above. The background
optical density (O.D.) value of compounds was subtracted from O.D. treatment and the
O.D. control to overcome any non-specific binding of crystal violet. The percent inhibition
was then calculated as follows [42]:
% inhibition = 100 − [(O.D. treatment/O.D. control) × 100] (1)
For biofilm eradication, a similar method was applied. Briefly, a bacterial inoculate was
added to each plate and incubated for 24 h at 37 ◦C under aerobic conditions on a rotator
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set at 20 rpm to create the biofilms. After 24 h, fresh test substances and combinations were
added using the same conditions as previously described for another 24 h after discarding
the supernatants. Next, the same crystal violet method and calculation steps were used to
obtain the percentage biofilm eradication.
2.7.2. Fluorescence Microscopy Analysis of Biofilm Eradication
A Live/Dead BacLightTM Bacterial Viability assay was performed to investigate the
effects of PRE, Zn (II) and PRE/Zn (II) combination on pre-existing 24 h-old biofilms using
glass-bottomed 96-well plates (Greiner Bio One Ltd., Stonehouse, UK). The assay was
performed based on the method previously described by Powell et al. [43]. Briefly, a 100 µL
aliquot of a bacterial suspension at 108 CFU/mL in MH broth was added into the plate and
aerobically incubated for 24 h at 37 ◦C After 24 h, supernatants were discarded and replaced
with PRE (MIC), Zn (II) (MIC), and PRE/Zn (II) combination (MIC + MIC) solutions and
incubated at 37 ◦C for 24 h. Then, each plate was stained using the Live/Dead BacLightTM
Bacterial Viability Kit according to manufacturer’s instructions and visualized using the
Leica TCS SP5 Confocal Microscope (Leica Microsystems Ltd., Milton Keynes, UK). Images
were obtained with a 60 × 1.8 oil objective and a z-step size of 1 µm. Z-stack images
obtained using Imaris software (Bitplane, Concord, MA, USA) were analyzed by using
Comstat2 plugin with the ImageJ analysis software, Version 2.1.0 (U. S. National Institutes
of Health, Bethesda, Maryland, USA) [44] and results are expressed as mean ± SEM
(n = 12).
2.8. Statistical Analysis
Experiments were performed in triplicate by using independent microbial cultures
for all antimicrobial assays. The results were analyzed and graphically presented with
the GraphPad Prism software (GraphPad Software, Version 8.2.1, San Diego, CA, USA).
A one-way ANOVA test with Tukey correction was used, and p < 0.05 was considered
statistically significant.
3. Results
3.1. Characterization of PRE
The Folin–Ciocalteu (F–C) assay showed that freeze-dried PRE contained an average
of 496 mg of TAE/g. The PRE extract was analyzed by reverse-phase HPLC [32], which
showed two characteristic major peaks corresponding to the α and β anomers of puni-
calagin, which are known to interconvert spontaneously to a ratio of punicalagin β to
punicalagin α content in the range of 2:1–1.6:1 [32,34,45]. In the current study, the ratio
of punicalagin β to punicalagin α content was found to be 1.76:1 (Figure 1). Using pure
punicalagin as a standard, it was determined that the amount of total punicalagin in a
1000 mg/L aqueous solution of PRE was 170 µg [32].
3.2. Determination of MIC and MBC Values of PRE and Zn (II)
The MIC values of PRE and Zn (II) against M. luteus are shown in Table 1. Inhibitory
activity was found at 1560 and 1790 mg/L for PRE and Zn (II), respectively. As expected,
the bactericidal concentrations of both compounds were higher than their inhibitory coun-
terparts. Thus, it could be suggested that each compound’s antimicrobial activities are
based on their inhibitory activities, rather than bactericidal activities.
Table 1. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations
(MBCs) values of PRE (mg/L) and Zn (II) (mg/L) against M. luteus in broth suspensions. Presented
data are the result of three independent experiments.
Compounds MIC (mg/L) MBC (mg/L)
PRE 1560 >1790
Zn (II) 440 >1790
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3.3. Determination of Synergistic Activity of PRE/Zn (II) in Combination
Both PRE and Zn (II) showed activity against M. luteus under planktonic conditions,
and the possibility of synergistic antimicrobial activity of PRE and Zn (II) in combination
was assessed using in vitro checkerboard and time-kill kinetic assays. The obtained FICin-
dex value was <0.5 (Table 2), and it was accepted as a demonstration of the synergistic
activity of the combination. At 240 min significant synergistic activity was observed in
the time-kill assay (Figure 2), where the PRE/Zn (II) combination gave a log reduction
of 6.88 ± 1.02 compared to 1.83 ± 0.24 for PRE alone and 3.4 ± 0.08 for Zn (II) alone
(p < 0.0001). Such synergy was not observed up to 1 h.
Table 2. FICindex values determined for PRE and Zn (II) alone and in combination using an in vitro
checkerboard assay against M. luteus.
FICI (PRE) FICI (Zn (II)) FICI Conclusion
M. luteus 0.0625 0.0625 0.125 Synergy
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and PRE/Zn (II) (MIC/2 + MIC/2) in combination against M. luteus. All data are represented as
mean ± SEM (n = 3). Note: synergistic activity at 240 min, showing a 6.88 ± 1.02 log reduction for
PRE/Zn (II), which was significantly greater than the 1.83 ± 0.24 log reduction for PRE and the
3.4 ± 0.08 log reduction for Zn (II); statistical significance indicated at *** p < 0.001 and **** p < 0.0001
between treatment groups.
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Pharmaceutics 2021, 13, 851 8 of 15




Figure 2. Log-reduction values obtained using time-kill assays for PRE (MIC/2), Zn (II) (MIC/2), 
and PRE/Zn (II) (MIC/2 + MIC/2) in combination against M. luteus. All data are represented as mean 
± SEM (n = 3). Note: synergistic activity at 240 min, showing a 6.88 ± 1.02 log reduction for PRE/Zn 
(II), which was significantly greater than the 1.83 ± 0.24 log reduction for PRE and the 3.4 ± 0.08 log 
reduction for Zn (II); statistical significance indicated at *** p < 0.001 and **** p < 0.0001 between 
treatment groups. 
3.4. Biofilm Inhibition and Eradication Activity of PRE, Zn (II) and PRE/Zn (II) in Combination 
3.4.1. Percentage of Biofilm Inhibition and Eradication through In Vitro Crystal Violet 
Assay 
Figure 3 shows that PRE (MIC/2, MIC), Zn (II) (MIC/2, MIC), and PRE/Zn (II) in 
combination (MIC + MIC and MIC/2 + MIC/2) each exhibited biofilm inhibition and 
eradication when using in vitro crystal violet assay. In this study, the test substances and 
their combination exerted significant inhibition and eradication activity compared to the 
untreated control group (p < 0.0001). However, synergistic activity was not observed 
between PRE and Zn (II), as no significant difference was observed between the PRE/Zn 
(II) combination and the compounds alone (p > 0.05). 
  
(a) (b) 
Figure 3. (a) Percentage biofilm inhibition and (b) biofilm eradication by PRE, Zn (II) and PRE/Zn (II) in combination at 
MIC and half of MIC values (MIC/2) against M. luteus, using the in vitro crystal violet assay. All data are represented as 
mean ± SEM, n = 3. Statistical significance indicated at ** p < 0.01, and **** p < 0.0001, compared to untreated growth con-






























































































































































Figure 3. (a) Percentage biofil inhibition and (b) biofil eradication by P E, n (II) and P E/ n (II) in co bination at
MIC and half of MIC values (MIC/2) against M. luteus, using the in vitro crystal violet assay. All data are represented as
mean ± SEM, n = 3. Statistical significance indicated at ** p < 0.01, and **** p < 0.0001, compared to untreated growth
controls and compared between treatment groups. Note: a significant effect of PRE, Zn (II), and the PRE/Zn (II) combination
in reducing biomass compared to untreated growth control group in biofilm inhibition and biofilm eradication activities.
3.4.2. Fluorescence Microscopy Analysis of Biofilm Eradication
The eradication activity of (MIC), Zn (II) (MIC), and PRE/Zn (II) in combination
(MIC + MIC) against the pre-formed M. luteus biofilm was examined using CLSM
(Figure 4a,b), and quantitative analysis was performed via COMSTAT analysis (Figure 4c).
In the control, M. luteus formed a thick and compact biofilm when not exposed to any
test substance challenge. However, all compounds and the combination significantly de-
creased the biomass of the biofilm compared to untreated controls, thus disrupting the
biofilm (all p < 0.0001). In particular, PRE and the PRE/Zn (II) combination caused a
significantly greater reduction in biomass than Zn (II) alone (p < 0.001). In addition, PRE
and Zn (II) increased the roughness coefficient, a parameter which is indicative of biofilm
heterogeneity. The combination of PRE and Zn (II) caused a statistically significant increase
in the roughness coefficient than both compounds alone (p < 0.05). However, no significant
differences were observed in the mean thickness values between substances and their
combination compared to untreated controls (p > 0.05).
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microscopy (CLSM) images in 3D (a) and 2D (b) views. Scale bars = 40 and 20 µm, respectively. PRE (MIC), Zn (II) (MIC),
and PRE/Zn (II) (MIC+MIC) were used. (c) Corresponding COMSTAT analyses of the images are shown. Mean ± SEM;
n = 12. Statistical significance indicated at * p < 0.05, *** p < 0.001, and **** p < 0.0001, compared to untreated controls and
compared between treatment groups. Note: 24-h-old M. luteus biofilm disruption following treatment with PRE, Zn (II),
and the PRE/Zn (II) combination, as indicated by a decreased biomass and an increased roughness coefficient. The PRE/Zn
(II) combination caused greater biofilm destruction compared to both the PRE and Zn (II) combination and the untreated
growth control group.
4. Discussion
The antimicrobial effects of pomegranate have been extensively studied, and different
parts of the pomegranate show antimicrobial activity against a range of Gram-positive and
Gram-negative bacteria [46–49]. The pomegranate rind has more polyphenol content than
other parts of the fruit and shows more antimicrobial activity than the seeds, whole fruit,
and juice extracts [50]. Melendez and Caprilles reported that pomegranate fruit extracts
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have a marked in vitro antimicrobial activity against a range of bacteria, including M. lu-
teus [49]. Negi and Jayaprakasha studied the antimicrobial activity of pomegranate peel
in different solvent extracts (acetone, methanol, and water) and found that all extracts ex-
hibited antimicrobial activity against both Gram-positive and Gram-negative bacteria [51].
Duman et al. studied aril extracts from six pomegranate cultivars and found antimicrobial
activity against M. luteus in all of them [52]. In accordance with the present results, previous
studies have demonstrated that the MIC of a pomegranate peel extract was 3130 mg/L
against M. luteus [53]. In this study, growth inhibition was observed for both PRE and Zn
(II) versus M. luteus, and the MIC was found to be similar at 1560 mg/L for PRE.
The current study has shown for the first time that PRE and Zn (II) results in synergis-
tic antibacterial (checkerboard assay) and bactericidal (time-kill assay) activities against
M. luteus, although the latter only after a prolonged exposure time of 4 h. The reason for
this timing is unclear, although the combination resulted in a highly significant doubling
of the log reduction. Synergistic virucidal activity between PRE and Zn (II) against Herpes
simplex virus was previously established with a time-kill assay by Houston et al. [28,32].
The PRE and zinc sulfate combination showed antimicrobial activity against B. subtilis,
Staphylococcus spp., and Brucella spp. in zone of inhibition assays [29], although the interpre-
tation of such analyses of complex mixtures and combined compounds in zone inhibition
assay is typically difficult due to the different diffusion rates of individual compounds and
combinations through the agar. McCarrell et al. studied the antimicrobial activity of PRE
with a range of metal salts against Gram-positive and Gram-negative bacteria and found
that PRE in combination with zinc sulfate provided no evidence of synergistic activity [29];
they also reported that PRE did not show any antimicrobial activity when used alone. How-
ever, they did observe an enhanced antimicrobial activity against P. aeruginosa, P. mirabilis,
and E. coli when PRE was combined with the (more toxic) copper (II) ions within 30 min
of exposure in a time-kill assay. The antimicrobial activity of PRE is highly associated
with its polyphenolic content, and punicalagin is by a long way the most abundant of all
compounds in PRE. It was suggested that gallagyl and galloyl-hexahydroxydiphenoyl
(HHDP) moieties of compounds in PRE have roles in antimicrobial activity. Recent studies
have reported the antimicrobial and antibiofilm activities of punicalagin against S. aureus
and other microbes [54,55]. It is possible the activity could also involve the synergistic
activity of polyphenolic compounds in PRE and its combination with Zn (II) rather than
just punicalagin. However, Houston et al. [28] found that PRE and punicalagin performed
similarly on a ‘mass-to-mass’ basis against HSV. Differences between MICs and the en-
hanced antimicrobial activity of PRE/Zn (II) could be caused by a range of factors including
different bacterial strains, the harvesting time of fruits, extraction methods, type of metal
salts, and type of solvents [56]. This variability could be circumvented using a standard-
ized extraction method from same cultivars of pomegranate fruit, and further analyses
are needed to probe potential structure–activity relationships between Zn (II) and other
secondary compounds in PRE.
Microbes behave differently and are generally more resistant against antimicrobial
agents and antibiotics under biofilm conditions than in their planktonic states [57,58]. It has
been hypothesized that M. luteus colonizes skin wounds by using the underlying basement
membrane substratum, which provides a foundation for the formation of a mature biofilm
that makes the environment more suitable for other, more pathogenic bacteria, such as
P. aeruginosa and S. aureus, which are predominant microbes in chronic skin wounds [59,60].
Thus, by inhibiting biofilm formation and eradicating the pre-formed biofilm of M. luteus,
the generation of more pathogenic biofilms could be prevented [61,62].
Antimicrobial and antibiofilm activities PRE and zinc have been reported against a
wide range of microbes. Zinc is an essential mineral that plays a vital role in the cellular
functions of life organisms, including bacteria; however, it can be toxic to bacteria in
higher concentrations, and the broad antimicrobial activity of zinc has been reported by
inhibiting the growth of bacteria and interfering with bacterial conjugation [63–66]. The
antibiofilm activity of zinc have been reported against different Gram-positive and Gram-
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negative microbes including S. aureus, S. mutans, and P. aeruginosa [67,68]. Several reports
have shown the anti-biofilm activity of pomegranate peel extracts. In an in vitro study,
pomegranate peel alcoholic extracts were assessed on bacteria collected from patients
with dental caries or periodontal disease, ultimately inhibiting a range of bacteria in both
planktonic and biofilm conditions [69]. In addition, PRE was shown to inhibit the formation
of biofilms of Staphylococcus aureus, MRSA, Escherichia coli, and Candida albicans, as well as
to disrupt the pre-formed biofilm of Candida albicans [70]. Punicalagin’s antimicrobial and
antibiofilm activities against S. aureus biofilm formation was also demonstrated [55].
Specifically, PRE, Zn (II), and PRE/Zn (II) in combination exerted both biofilm inhibi-
tion and biofilm eradication activities, as confirmed by both spectrophotometric assays and
Live/Dead staining with CLSM. PRE and PRE/Zn (II) in combination also caused greater
decreases in biofilm biomass than Zn (II) alone. This may be explained by the fact that the
inhibitory activity on biofilm formation for combined PRE/Zn (II) could be attributed to
the activity of PRE rather than Zn (II). However, it should be noted that PRE/Zn (II) in
combination significantly affected the roughness coefficient when compared to PRE or Zn
(II) alone.
A roughness coefficient provides information about the variability of thickness of
the biofilm, is a sign of biofilm heterogeneity [44], and is a commonly used criterion to
describe a biofilm’s structure when comparing biofilms [71–73]. While PRE, Zn (II), and the
PRE/Zn (II) combination reduced the mean thickness of biomass, they did not cause any
significant differences compared to control group, possibly because the mean thickness is a
3-dimensional aspect of the biofilm [41] and the compounds and combination in this study
caused areal eradication in biofilm that could be observed from the 3D and 2D images, as
shown in Figure 4a,b.
M. luteus was found and associated with the central venous catheter infection [13,74,75].
Reducing the colonization insertion hub, the site of the catheter, the inhibition of adhesion,
and the growth of pathogens that reach the catheter have been suggested as successful
preventive strategies for catheter-related infectious diseases [76]. In this study, the PRE/Zn
(II) combination exerted potentiated activity in reducing colonization and inhibiting growth
control. The anti-adhesive activity of PRE has been confirmed in the literature [77,78]. PRE’s
activity on biofilm formation, inhibition and eradication could support the potential efficacy
of PRE and the PRE/Zn (II) combination as a preventive agent in catheter-related infectious
diseases caused by M. luteus, e.g., as a coating on the catheter surface prior to use.
The antimicrobial activity of PRE against M. luteus has been shown in previous
studies [47,51], but PRE/Zn (II) combinations also gave synergistic antimicrobial activity
in planktonic condition against M. luteus showed in this study. Moreover, to the best of
our knowledge, our study is the first to demonstrate the anti-biofilm properties of PRE
and the PRE/Zn (II) combination on biofilms. The antimicrobial mechanism of action
for PRE and PRE/Zn (II) is still to be confirmed, although there have been reports that
suggested that PRE induces protein precipitation and enzyme inactivation [47,79]. With
such protein precipitation and inhibition activities, PRE could inhibit proteins involved in
biofilm formation, such as adhesins [80]. This may explain the reduced biofilm formation
capabilities of M. luteus following treatment with PRE and PRE/Zn (II). Furthermore, it has
been shown that tannins are capable of modifying the surface charge of proteins, which
helps prevent cell–substratum interactions and biofilm formation [47,79,80]. In general,
the antimicrobial activity of PRE has been associated with pomegranate ellagitannins,
especially punicalagin (its major tannin constituent) and ellagic acid [48,79,81].
Punicalagin and PRE have been shown to downregulate inflammatory mediators [27,82],
and enhanced activity between PRE and Zn (II) was reported in in vitro wound healing
experiments [83]. However, the mechanism involved the synergistic antimicrobial effect
of PRE/Zn (II) in combination is currently unclear. One suggested mechanism is that
pomegranate tannins form ‘complexes’ with metallic ions that may exhibit enhanced
toxicity towards microbes [84]. Alternatively, the enhanced activity may be independent
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of complex formation, with components of PRE, e.g., punicalagin and Zn (II), acting
independently against different aspects of the bacteria life processes [85,86].
5. Conclusions
Both PRE and Zn (II) showed antimicrobial activity against M. luteus under planktonic
and biofilm conditions. PRE/Zn (II) in combination only showed synergistic microbicidal
and antimicrobial activity under planktonic conditions. Though the PRE/Zn (II) combina-
tion did not show an enhanced antimicrobial activity in the inhibition of biofilm formation,
it did significantly alter biofilm physical characteristics by increasing the roughness coef-
ficient compared to biofilm treated with PRE or Zn (II) alone. Overall, the antimicrobial
activity of PRE and PRE/Zn (II) against biofilm formation and pre-formed biofilms could
represent a promising new treatment for disease-associated infections caused by M. luteus.
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